Anti-inflammatory effects of α-galactosylceramide analogs in activated microglia: Involvement of the p38 MAPK signaling pathway

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Jeong, Yeon Hui ^a   Kim, Yongju ^b,d   Song, Heebum ^b   Chung, Young Sun ^c   Park, Seung Bum ^b   Kim, Hee Sun ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Korea Cyber University (KCU)   (South Korea)

^d Jilin University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ALPHA GALACTOSYLCERAMIDE; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; COX 2 GENE; DNA BINDING; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; INOS GENE; INTERLEUKIN 1BETA GENE; INTERLEUKIN 6 GENE; MICROGLIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; DNA; GALACTOSYLCERAMIDES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMIDAZOLES; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MAP KINASE SIGNALING SYSTEM; MICE; MICROGLIA; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; TRANSCRIPTION FACTOR AP-1;

EID: 84895828675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087030     Document Type: Article

References (45)

1. Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, et al. (2011) The role of microglia in the healthy brain. J Neurosci 31: 16064-16069.
2. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
3. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69. (Pubitemid 46011999)
4. Graeber MB, Streit WJ (2010) Microglia: biology and pathology. Acta Neuropathol 119: 89-105.
5. Cunningham C (2013) Microglia and Neurodegeneration: The role of systemic inflammation. Glia 61: 71-90.
6. Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, et al. (2009) Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Phychiatry 65: 304-312.
7. Lull ME, Block ML (2010) Microglial activation and chronic neurodegeneration. Neurotherapeutics 7: 354-365.
8. Watkins LR, Maier SF (2003) Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2: 973-985. (Pubitemid 37540579)
9. Tsuda M, Inoue K, Salter MW (2005) Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci 28: 101-107. (Pubitemid 40178927)
10. Van Kaer L (2005) alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 5: 31-42.
11. Hayakawa Y, Rovero S, Forni G, Smyth MJ (2003) Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci U S A 100: 9464-9469. (Pubitemid 37033951)
12. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, et al. (2004) Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21: 539-550. (Pubitemid 39370509)
13. Kitamura H, Iwakabe K, Yahata T, Nishimura S-I, Ohta A, et al. (1999) The natural killer T (NKT) cell ligand a-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Med Exp 189: 1121-1127. (Pubitemid 29169829)
14. NaKagawa R, Serizawa I, Motoki K, Sato M, Ueno H, et al. (2000) Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol Res 12: 51-58.
15. Delovitch TL, Singh B (1997) The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7: 727-738. (Pubitemid 28064887)
16. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, et al. (2001) Activation of natural diller T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Med Exp 194: 1789-1799. (Pubitemid 34028658)
17. Singh AK, Wilson MT, Hong S, Olivares-Villagómez D, Du C, et al. (2001) Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Med Exp 194: 1801-1811. (Pubitemid 34028659)
18. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, et al. (2004) Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum 50: 305-313. (Pubitemid 38084316)
19. Kawano T (1997) CD1d-restricted and TCR-mediated activation of V14 NKT cells by glycosylceramides. Science 278: 1626-1629.
20. Yu KOA, Porcelli SA (2005) The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol Lett 100: 42-55. (Pubitemid 41262033)
21. Bocchni V, Mazzolla R, Barluzzi R, Blasi E, Sick P, et al. (1992) An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 6: 16-21.
22. Park JS, Park EM, Kim DH, Jung K, Jung JS, et al. (2009) Anti-inflammatory mechanism of ginseng saponins in activated microglia. J Neuroimmunol 209: 40-49.
23. Lee KM, Kang HS, Yun CH, Kwak SH (2012) Potential in vitro protective effect of quercetin, catechin, caffeic acid and phytic acid against ethanol-induced oxidative stress in SK-Hep1 cells. Biomol Ther 20: 492-498.
24. Woo M-S, Jang P-G, Park J-S, Kim W-K, Joh TH, et al. (2003) Selective modulation of lipopolysaccharide-stimulated cytokine expression and mitogen-activated protein kinase pathways by dibutyryl-cAMP in BV2 microglial cells. Mol Brain Res 113: 86-96. (Pubitemid 36579070)
25. Kim Y, Kim J, Oh K, Lee D-S, Park SB (2012) Heteroaromatic moieties in the sphingosine backbone of a-galactosylceramides for noncovalent interactions with CD1d. ACS Med Chem Lett 3: 151-154.
26. Kim Y, Oh K, Song H, Lee D-S, Park SB (2013) Synthesis and biological evaluation of a-galactosylceramide analogues with heteroaromatic rings and varying positions of a phenyl group in the sphingosine backbone. J Med Chem 56: 7100-7109.
27. Goff RD, Gao Y, Mattner J, Zhou D, Yin N, et al. (2004) Effects of lipid chain lengths in a-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 126: 13602-13603. (Pubitemid 39407224)
28. Fujio M, Wu D, Garcia-Navarro R, Ho DD, Tsuji M, et al. (2006) Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc 128: 9022-9023. (Pubitemid 44078971)
29. Opitz B, Schroder NW, Spreitzer I, Michelsen KS, Kirschning CJ, et al. (2001) Toll-like receptor-2 mediates treponema glycolipid and lipoteichoic acid-induced NF-kappaB translocation. J Biol Chem 276: 22041-22047.
30. Knapp S, Aulock SV, Leendertse M, Haslinger I, Draing C, et al. (2008) Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol 180: 3478-3484.
31. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3. Nature 413: 732-738. (Pubitemid 33009951)
32. Olson JK, Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173: 3916-3924. (Pubitemid 39280755)
33. Zarubin T, Han J (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res 15: 11-18. (Pubitemid 41653958)
34. Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-726. (Pubitemid 37361787)
35. Saklatvala J (2004) The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 4: 372-377.
36. Adams JL, Badger AM, Kumar S, Lee JC (2001) p38 MAP kinases: molecular target for the inhibition of proinflammatory cytokines. Prog Med Chem 38: 1-60.
37. Bachstetter AD, Eldik LJV (2010) The p38 MAP kinase family as regulators of proinflammatory cytokine production in degenerative diseases of the CNS. Aging Dis 1: 199-211.
38. Anderson P (2008) Post-transcriptional control of cytokine production. Nat Immunol 4: 353-359.
39. Espel E (2005) The role of the AU-rich elements of mRNAs in controlling translation. Semin Cell Dev Biol 16: 59-67.
40. Kumar S, Boehm J, Lee JC (2003) p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2: 717-725.
41. Cuny GD (2009) Kinase inhibitors as potential therapeutics for scute and vhronic neurodegenerative conditions. Curr Pharm Des 15: 3919.
42. Jung JS, Shin KO, Lee YM, Shin JA, Park EM, et al. (2013) Anti-inflammatory mechanism of exogenous C2 ceramide in lipopolysaccharide- stimulated microglia. Biochim Biophys Acta 1831: 1016-1026.
43. Lu YC, Yeh WC, Ohashi PS (2008) LPS/TLR4 signal transduction pathway. Cytokine 42: 145-151.
44. Joseph CK, Wright SD, Bornmann WG, Randolph JT, Kurnar ER, et al. (1994) Bacterial lipopolysaccharide has structural similarityt to ceramide and stimulates ceramide-activated protein kinase in myeloid cells. J Biol Chem 269: 17606-17610. (Pubitemid 24218044)
45. Hung LC, Lin CC, Hung SK, Wu BC, Jan MD, et al. (2007) A synthetic analog of alpha-galactosylceramide induces macrophage activation via the TLR4-signaling pathways. Biochem Pharmacol 73: 1957-1970.